Spots Global Cancer Trial Database for Savolitinib vs. Sunitinib in MET-driven PRCC.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Savolitinib vs. Sunitinib in MET-driven PRCC.
Official Title: A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Study ID: NCT03091192
Study Description
Brief Summary: This study is designed for patients diagnosed with MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma. The purpose of this study is to see if an investigational new anti-cancer medication, savolitinib, is effective in treating patients with MET-driven PRCC, how it compares with another medication frequently used to treat this disease called sunitinib, and what side effects it might cause.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, La Jolla, California, United States
Research Site, Atlanta, Georgia, United States
Research Site, Chicago, Illinois, United States
Research Site, Iowa City, Iowa, United States
Research Site, Boston, Massachusetts, United States
Research Site, Kansas City, Missouri, United States
Research Site, New York, New York, United States
Research Site, Nashville, Tennessee, United States
Research Site, Barretos, , Brazil
Research Site, Curitiba, , Brazil
Research Site, Passo Fundo, , Brazil
Research Site, Pelotas, , Brazil
Research Site, Porto Alegre, , Brazil
Research Site, Porto Alegre, , Brazil
Research Site, Porto Alegre, , Brazil
Research Site, Rio de Janeiro, , Brazil
Research Site, Sao Paulo, , Brazil
Research Site, São José do Rio Preto, , Brazil
Research Site, São Paulo, , Brazil
Research Site, Bordeaux, , France
Research Site, Vandoeuvre les Nancy, , France
Research Site, Villejuif, , France
Research Site, Arezzo, , Italy
Research Site, Meldola, , Italy
Research Site, Milano, , Italy
Research Site, Modena, , Italy
Research Site, Orbassano, , Italy
Research Site, Pavia, , Italy
Research Site, Roma, , Italy
Research Site, Daejeon, , Korea, Republic of
Research Site, Goyang-si, , Korea, Republic of
Research Site, Hwasun-gun, , Korea, Republic of
Research Site, Incheon, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Krasnoyarsk, , Russian Federation
Research Site, Moscow, , Russian Federation
Research Site, Moscow, , Russian Federation
Research Site, Moscow, , Russian Federation
Research Site, Moscow, , Russian Federation
Research Site, Murmansk, , Russian Federation
Research Site, Nizhnii Novgorod, , Russian Federation
Research Site, Obninsk, , Russian Federation
Research Site, Omsk, , Russian Federation
Research Site, Saint Petersburg, , Russian Federation
Research Site, Sankt-Peterburg, , Russian Federation
Research Site, St. Petersburg, , Russian Federation
Research Site, Volgograd, , Russian Federation
Research Site, Dnipro, , Ukraine
Research Site, Dnipro, , Ukraine
Research Site, Ivano-Frankivsk, , Ukraine
Research Site, Kharkiv Region, , Ukraine
Research Site, Kyiv, , Ukraine
Research Site, Kyiv, , Ukraine
Research Site, Odesa, , Ukraine
Research Site, Sumy, , Ukraine
Contact Details
Name: Toni K Choueiri, MD
Affiliation: Dana-Farber Cancer Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
